← FDA DRUG APPROVALS

FDA NDA · NDA022072

SPRYCEL

Sponsor: BRISTOL MYERS SQUIBB

APPLICATION
NDA022072
TYPE
NDA
ORIGINAL APPROVAL
2006-06-28
LATEST ACTION
2010-07-28
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SPRYCELPrescription
DASATINIB 70MG · TABLET · ORAL

Approval history

2010-07-28Labeling · Supplement 2 · standard — Letter ↗AP
2008-05-30Manufacturing (CMC) · Supplement 1 — Letter ↗AP
2006-06-28Type 6 - New Indication (no longer used) · Original · priority — Review ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →